Calithera Biosciences Company Profile (NASDAQ:CALA)

Analyst Ratings

Consensus Ratings for Calithera Biosciences (NASDAQ:CALA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (280.95% upside)

Analysts' Ratings History for Calithera Biosciences (NASDAQ:CALA)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$20.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Leerink SwannLower Price TargetOutperform$19.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Citigroup Inc.Initiated CoverageBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Calithera Biosciences (NASDAQ:CALA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.47)($0.52)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.56)($0.44)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.52)($0.49)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.45)($0.44)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2014($0.28)($16.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Calithera Biosciences (NASDAQ:CALA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.52)($0.52)($0.52)
Q3 20161($0.56)($0.56)($0.56)
Q4 20161($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Calithera Biosciences (NASDAQ:CALA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Calithera Biosciences (NASDAQ:CALA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/16/2015Curtis HechtVPSell970$6.58$6,382.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Adage Capital Partners Gp LlcMajor ShareholderBuy106,968$6.03$645,017.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Adage Capital Partners Gp LlcMajor ShareholderBuy90,300$5.93$535,479.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Adage Capital Partners Gp LlcMajor ShareholderBuy172,126$5.27$907,104.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014Adage Capital Partners Gp LlcMajor ShareholderBuy181,700$6.96$1,264,632.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Jean GeorgeDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Morgenthaler Venture PartnersMajor ShareholderBuy350,000$10.00$3,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Adage Capital Partners Gp LlcMajor ShareholderBuy800,000$10.00$8,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Calithera Biosciences (NASDAQ:CALA)
DateHeadline
07/21/16 08:36 PMChecking in on Stock Volatility for: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/20/16 04:07 PMBiotech news that matter for investors: Calithera Biosciences, Inc. (NASDAQ:CALA), Relypsa, Inc. (NASDAQ:RLYP) - The Voice Registrar
07/19/16 03:07 PMHeightened Volatility Spotted on Shares of: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/19/16 09:15 AMInvestor Watch: Volatility Recap on Shares of: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/18/16 08:03 AMCalithera Biosciences Inc: A Big Bounce Could Be Brewing
07/17/16 02:53 PMIncreased Volatility Noted on Shares of: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/16/16 03:00 PMIt Seems Calithera Biosciences Inc Will Go Down. Have Another Big Decline - Consumer Eagle
07/16/16 03:00 PMNoting Unusual Volume on Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/16/16 03:00 PMShares Experiencing a Downtrend: Calithera Biosciences, Inc. (NASDAQ:CALA) - TGP
07/16/16 03:00 PMShares Moving Down on the Week: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/16/16 03:00 PMWhich way Calithera Biosciences, Inc. (NASDAQ:CALA) insiders are heading - Review Fortune
07/14/16 08:32 PMCalithera Biosciences Incorporated (NASDAQ:CALA) Short Interest Decreased By 3.29% - Consumer Eagle
07/14/16 08:32 PMEye on Stock Volatility for: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/14/16 03:04 PMImmunoGen, CVR Top Thursday’s 52-Week Low Club -
07/13/16 03:06 PMCalithera Biosciences, Inc. (CALA) Hits a New 52-Week Low - Finance Daily
07/13/16 03:06 PMCalithera Biosciences (NASDAQ:CALA) First Quarter Institutional Investor Sentiment Steady - Consumer Eagle
07/13/16 03:06 PMStrong Sell Calls For Calithera Biosciences, Inc. (NASDAQ:CALA) At 0 - Investor Newswire
07/12/16 07:13 AMCalithera Biosciences, Inc. (CALA) Sees New 52-Week Low - Finance Daily
07/12/16 07:13 AMWere Analysts Bullish Calithera Biosciences Inc (NASDAQ:CALA) This Week? - Press Telegraph
07/10/16 02:56 PMCalithera Biosciences Incorporated (NASDAQ:CALA) Shorts Decreased by 3.29% After Short Covering - Press Telegraph
07/09/16 07:32 AMCalithera Biosciences, Inc. (CALA) Reached a New 52-Week Low - Finance Daily
07/07/16 08:17 PMCalithera Biosciences (CALA) : Analyst Rating Update - Trade Calls
07/07/16 08:17 PMFollowing Unusual Volume for: Calithera Biosciences, Inc. (NASDAQ:CALA) - Engelwood Daily
07/06/16 08:50 PMCalithera Biosciences, Inc. (NASDAQ:CALA) Expected to Reach Highs Of $11 - Investor Newswire
07/06/16 03:08 PMWhat's Next for Calithera Biosciences Inc After Reaching All-Time Low? - Press Telegraph
07/04/16 02:54 PMBroker Outlook For The Week Ahead Calithera Biosciences, Inc. (NASDAQ:CALA) - Fiscal Standard
07/01/16 11:07 AMNew Broker Ratings For Calithera Biosciences, Inc. (NASDAQ:CALA) - FTSE News
06/29/16 08:06 PMCalithera Biosciences Incorporated (NASDAQ:CALA) Sellers Covered 3.29% of Their Shorts - Press Telegraph
06/29/16 03:01 PMCalithera Biosciences Inc Can't Be More Risky. Trades Sigfnicicantly Lower - Press Telegraph
06/29/16 10:15 AMCalithera Biosciences (CALA) Jumps: Stock Rises 7.6% - Nasdaq
06/29/16 10:15 AMCalithera Biosciences Inc Has Another Very Strong Trading Session - Press Telegraph
06/28/16 07:31 PMCalithera Biosciences, Inc. (CALA) Reaches New 52-Week Low - Finance Daily
06/28/16 07:31 PMCould Calithera Biosciences Inc See a Reversal After This Very Strong Session? - Engelwood Daily
06/23/16 03:20 PMTrending Tickers: Calithera Biosciences, Inc. (NASDAQ:CALA), Brightcove Inc. (NASDAQ:BCOV), Pacira ... - KC Register
06/23/16 11:04 AMStrong Buy Calls Count For Calithera Biosciences, Inc. (NASDAQ:CALA) At 2 - Investor Newswire
06/16/16 03:07 PMCALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 11:33 AMCalithera Biosciences, Inc. (NASDAQ:CALA) decreased -7.34%: Target Corp. (NYSE:TGT), YOU On Demand Holdings ... - KC Register
06/08/16 05:04 PMCalithera Biosciences, Inc. :CALA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/06/16 02:54 PMCalithera Biosciences (CALA) Announces Presentation of Positive CB-839 Data in TNBC at ASCO - StreetInsider.com
06/06/16 08:26 AMCalithera Reports CB-839 Phase I Solid Tumor Combo Data at ASCO
06/06/16 06:31 AM7:31 am Calithera Biosciences ASCO data demonstrated the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with renal cell carcinoma and triple negative breast cancer (:TNBC) -
06/06/16 06:30 AMCalithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting - [GlobeNewswire] - Future development to focus on renal cell carcinoma and triple negative breast cancer Calithera to host investor webcast on June 6, 2015 at 6:30 p.m. CT. SOUTH SAN FRANCISCO, Calif., June 06, 2016-- Calithera ...
06/01/16 09:11 PMCalithera Biosciences, Inc. (NASDAQ:CALA) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Calithera Biosciences, Inc. (NASDAQ:CALA) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Calithera Biosciences, Inc. (NASDAQ:CALA). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/28/16 10:16 AMCalithera Biosciences, Inc. (NASDAQ:CALA) Closes At $5.07 - Investor Newswire - Calithera Biosciences, Inc. (NASDAQ:CALA) Closes At $5.07Investor NewswireYesterday, the stock of Calithera Biosciences, Inc. (NASDAQ:CALA) closed at $5.07 after opening at $5.06 and registering high of $5.12 and low of $4.95. The last price is $-6.19 off 1-year high of $11.17 and $0.91 away from low of $4.07 during same period.
05/26/16 10:25 AMCalithera Biosciences, Inc. (NASDAQ:CALA) Quarterly EPS From Continuing Operations Stands At $-0.5211 - RealistInvestor.com - Calithera Biosciences, Inc. (NASDAQ:CALA) Quarterly EPS From Continuing Operations Stands At $-0.5211RealistInvestor.comFor the year ended 2016-03-31 Calithera Biosciences, Inc. (NASDAQ:CALA) basic consolidated EPS reported was $-1.809. For the quarter ended 2016-03-31, it came at $-1.809. EPS is a part of a firm's earnings that is owed to each outstanding stock.
05/10/16 03:38 PMCalithera Biosciences Reports First Quarter 2016 Financial Results and Recent Highlights - [at noodls] - - CB-839 Phase 1b Clinical Data to be Presented at ASCO 2016 - Key clinical leadership expansion - Calithera to Host Conference Call Today at 4:30pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 10, 2016 ...
05/10/16 03:30 PMCalithera Biosciences Inc Earnings Call scheduled for 4:30 pm ET today -
05/10/16 06:07 AMQ1 2016 Calithera Biosciences Inc Earnings Release - Time Not Supplied -
05/03/16 08:10 AMCalithera Biosciences to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule ...
04/21/16 08:27 AMCalithera Biosciences Announces Clinical Data Presentations at ASCO 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule ...

Social

About Calithera Biosciences

Calithera Biosciences logoCalithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CALA
  • CUSIP:
Key Metrics:
  • Previous Close: $3.07
  • 50 Day Moving Average: $4.09
  • 200 Day Moving Average: $5.11
  • P/E Ratio: N/A
  • P/E Growth: -0.02
  • Market Cap: $59.71M
  • Beta: 2.71
  • Current Year EPS Consensus Estimate: $-2.15 EPS
  • Next Year EPS Consensus Estimate: $-1.88 EPS
Additional Links:
Calithera Biosciences (NASDAQ:CALA) Chart for Sunday, July, 24, 2016